NewAmsterdam Pharma Co. N.V. (KH6)

Overview

NewAmsterdam Pharma Company N.V. stands out as a pioneering late-stage biopharmaceutical entity committed to enhancing patient care across populations grappling with metabolic diseases. Positioned at the forefront of therapeutic innovation, the company is actively engaged in the development of cutting-edge treatments designed to address a broad spectrum of cardiovascular and metabolic disorders. With its headquarters nestled in Naarden, the Netherlands, NewAmsterdam Pharma Company N.V. is making significant strides in transforming patient outcomes through its dedicated research and development endeavors.

Products and Services

• Obicetrapib as a Monotherapy:

  This innovative product under development is an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor. Specifically tailored for patients with cardiovascular diseases, obicetrapib is meticulously designed to lower low-density lipoprotein cholesterol (LDL-C) levels. The drug is currently undergoing various clinical trials to meticulously evaluate its efficacy as a standalone treatment option, promising a new horizon in the management of cardiovascular conditions.

• Obicetrapib in Combination with Ezetimibe:

  Exploring the synergistic potential, obicetrapib is also being tested in combination with ezetimibe, a well-known lipid-lowering medication. This innovative therapy aims to offer an enhanced approach to reducing LDL-C levels in patients with cardiovascular diseases. By combining the unique mechanisms of obicetrapib and ezetimibe, this therapy seeks to present a formidable strategy in the fight against cardiovascular morbidity and mortality.

• Obicetrapib for Alzheimer's Disease:

  In a remarkable extension of its therapeutic application, obicetrapib is under investigation in a Phase 2a clinical trial targeting Alzheimer's disease. This exploratory development reflects NewAmsterdam Pharma Company N.V.'s commitment to leveraging its expertise in metabolic disease therapies for broader medical challenges. The study aims to uncover the potential benefits of obicetrapib in mitigating the progression or symptoms of Alzheimer's disease, thereby opening new avenues in the treatment of neurodegenerative disorders.